United States was Resmed’s largest region in fiscal 2026, bringing in $3.56B of $5.65B (63%).
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.72B | $2.98B | $3.29B | $3.56B | |||||||||||
| U.S., Canada & Latin America | — | — | — | — | |||||||||||
| Rest Of The World | $1.50B | $1.71B | $1.86B | $2.09B | |||||||||||
| Combined Europe, Asia & Other Markets | — | — | — | — | |||||||||||
| Rest Of World | — | — | — | — | |||||||||||
| North & Latin America | — | — | — | — | |||||||||||
| Germany | — | — | — | — | |||||||||||
| France | — | — | — | — | |||||||||||
| Australia | — | — | — | — | |||||||||||
| Total | $4.22B | $4.69B | $5.15B | $5.65B |
Resmed brought in $5.65B from its two regions in fiscal 2026, the year ended June 30, 2026. That was up 9.9% from $5.15B in fiscal 2025. United States was the largest at $3.56B (63.0%), ahead of Rest Of The World at $2.09B (37.0%).
Compared with fiscal 2025, Rest Of The World grew 12.4% to $2.09B and United States grew 8.4% to $3.56B. From fiscal 2023 to 2026, combined revenue from these regions grew from $4.22B to $5.65B, a compound annual growth rate of 10.2%. United States' share of the total fell from 64.4% to 63.0%.
Sleep & Breathing Health was Resmed’s largest product and service line in fiscal 2026, bringing in $4.98B of $5.65B (88%).
| Product and Service | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sleep & Breathing Health | $3.73B | $4.10B | $4.50B | $4.98B | |||||||||||||
| Sleep & Respiratory Care | — | — | — | — | |||||||||||||
| Sleep & Respiratory Care Products | — | — | — | — | |||||||||||||
| Devices | — | — | — | — | |||||||||||||
| Flow Generators | — | — | — | — | |||||||||||||
| Masks & Other Accessories | — | — | — | — | |||||||||||||
| Mask Systems, Motors & Other Accessories | — | — | — | — | |||||||||||||
| Residential Care Software | $497.98M | $584.13M | $641.44M | $675.81M | |||||||||||||
| Software As A Service | — | — | — | — | |||||||||||||
| Total | $4.22B | $4.69B | $5.15B | $5.65B |
Resmed brought in $5.65B from its two product and service lines in fiscal 2026, the year ended June 30, 2026. That was up 9.9% from $5.15B in fiscal 2025. Sleep & Breathing Health was the largest at $4.98B (88.0%), ahead of Residential Care Software at $675.81M (12.0%).
Compared with fiscal 2025, Sleep & Breathing Health grew 10.5% to $4.98B and Residential Care Software grew 5.4% to $675.81M. From fiscal 2023 to 2026, combined revenue from these lines grew from $4.22B to $5.65B, a compound annual growth rate of 10.2%. Sleep & Breathing Health's share held steady at about 88.0%.
Sleep & Breathing Health was Resmed’s largest segment in fiscal 2026, bringing in $4.98B of $5.65B (88%).
| Segment | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sleep & Breathing Health | $3.73B | $4.10B | $4.50B | $4.98B | ||||||
| Sleep & Respiratory Care | — | — | — | — | ||||||
| Total Sleep & Respiratory Care | — | — | — | — | ||||||
| Devices | — | — | — | — | ||||||
| Masks & Other | — | — | — | — | ||||||
| Residential Care Software | $497.98M | $584.13M | $641.44M | $675.81M | ||||||
| Software As A Service | — | — | — | — | ||||||
| Total | $4.22B | $4.69B | $5.15B | $5.65B |
Resmed brought in $5.65B from its two segments in fiscal 2026, the year ended June 30, 2026. That was up 9.9% from $5.15B in fiscal 2025. Sleep & Breathing Health was the largest at $4.98B (88.0%), ahead of Residential Care Software at $675.81M (12.0%).
Compared with fiscal 2025, Sleep & Breathing Health grew 10.5% to $4.98B and Residential Care Software grew 5.4% to $675.81M. From fiscal 2023 to 2026, combined revenue from these segments grew from $4.22B to $5.65B, a compound annual growth rate of 10.2%. Sleep & Breathing Health's share held steady at about 88.0%.
Resmed (RMD) reports its revenue by geography, by product and service and by segment. In fiscal 2026, United States was its largest region, bringing in $3.56B (63.0% of the total), followed by Rest Of The World at $2.09B (37.0%).
United States was Resmed's largest region in fiscal 2026, bringing in $3.56B, or 63.0% of the $5.65B total across its two regions.
Sleep & Breathing Health was Resmed's largest product and service line in fiscal 2026, bringing in $4.98B, or 88.0% of the $5.65B total across its two product and service lines.
Sleep & Breathing Health was Resmed's largest segment in fiscal 2026, bringing in $4.98B, or 88.0% of the $5.65B total across its two segments.
Rest Of The World grew faster than United States in fiscal 2026, up 12.4% from $1.86B to $2.09B. United States grew 8.4% to $3.56B.
Every figure comes from Resmed's annual financial filings, as reported. Each line keeps the name Resmed gives it, and years follow its fiscal calendar.
Resmed's revenue by geography goes back to fiscal 2012, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.